Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Genetron Holdings Ltd.
Headquarters: Beijing, China
Website: https://www.genetronhealth.co...
Year Founded: 2013
Status: Private
BioCentury | Nov 30, 2022
Discovery & Translation
Acuitas’ pan-influenza mRNA vaccine; plus Opna links FMR1 to cancer and more
BioCentury’s roundup of translational news
BioCentury | Aug 26, 2022
Finance
U.S., China audit deal puts fall inspections in spotlight
SEC says agreement needs to be tested in practice before determining compliance by year-end
BioCentury | Mar 16, 2022
Deals
March 15 Quick Takes: Blackstone backs Sanofi’s multiple myeloma trial
Plus: Keytruda, Lynparza combo misses, pandemic antiviral initiative launches and updates from Eisai, Biogen and more
BioCentury | Jul 31, 2021
Finance
What’s next for China’s biopharmas after a roller-coaster week
Volatile week underscores why U.S.-listed China companies should prepare for greater transparency and consider capital markets contingency plans
BioCentury | Jul 27, 2021
Finance
China’s market jitters clip biopharma shares
Bellwethers tumble, biotech ETFs down 7% after Beijing’s latest regulatory move
BioCentury | Jan 7, 2021
Deals
Jan. 6 Quick Takes: Ribometrix gets $25M up front in Genentech RNA deal; plus Dewpoint-Pfizer, Kite-Oxford BioTherapeutics, Illumina-Helix and more
Ribometrix, Genentech partner for RNA-targeting small moleculesRibometrix Inc. and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) are partnering to develop small molecules against undisclosed
BioCentury | Oct 8, 2020
Product Development
Mapping opportunities for China’s early cancer detection boom
How Chinese companies developing liquid biopsies for cancer are approaching the potentially massive market
BioCentury | Oct 2, 2020
Regulation
Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more
Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to
BioCentury | Aug 15, 2020
Finance
As CBMG moves to complete go-private deal, pressure on U.S.-listed Chinese companies mounts in Washington
$383M deal set against backdrop of White House, Senate push to tighten auditing rules
BioCentury | Jun 20, 2020
Finance
Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum
Beijing-based Genetron debuts with $1.4B valuation as quartet of biotechs price offerings
Items per page:
1 - 10 of 18